600267 海正药业
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)7.2336.3817.312-1.1526.356
总资产报酬率 ROA (%)4.4473.4863.580-0.5122.563
投入资产回报率 ROIC (%)5.5114.3074.374-0.6363.196

边际利润分析
销售毛利率 (%)55.57644.83442.45641.54244.222
营业利润率 (%)18.4978.2196.9760.8905.998
息税前利润/营业总收入 (%)19.1028.5268.1911.0828.315
净利润/营业总收入 (%)14.3385.1905.719-0.9654.317

收益指标分析
经营活动净收益/利润总额(%)86.937134.778107.212-278.042113.401
价值变动净收益/利润总额(%)21.208-8.76719.849-90.002-11.155
营业外收支净额/利润总额(%)-0.518-6.336-0.454207.9360.138

偿债能力分析
流动比率 (X)0.9340.9280.9220.9660.899
速动比率 (X)0.6130.6380.6300.6690.630
资产负债率 (%)31.84341.19146.28952.59655.638
带息债务/全部投入资本 (%)16.49426.89334.15041.74543.843
股东权益/带息债务 (%)493.954265.322187.257134.380124.129
股东权益/负债合计 (%)208.011138.829112.82187.45877.330
利息保障倍数 (X)27.28010.7036.5690.5683.601

营运能力分析
应收账款周转天数 (天)56.94160.81264.24578.29071.945
存货周转天数 (天)135.836107.670113.488118.569111.653